NCT01213732已完成1 期
Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma.
Philogen S.p.A.3 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2008年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 3
- 主要终点
- Safety and Tolerability
研究概览
简要总结
In this study the recombinant human fusion protein L19TNFα will be associated in ILP with the standard treatment with melphalan 10mg/l limb volume in subjects affected by stage III/IV limb melanoma.
The recombinant human fusion protein L19TNFα was created with the intention to target TNFα directly to tumor tissues with the result in high and sustained intralesional bioactive TNFα concentrations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged >18 years.
- •Histologically or cytologically confirmed intransit stage III/IV melanoma of lower extremity distal to the apex of the femoral triangle
- •ECOG performance status ≤
- •Subjects must have at least one unidimensional clinically measurable lesion as defined by RECIST criteria (see Section 8). This lesion must not have been irradiated within four weeks during previous treatments.
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and haemoglobin (Hb) ≥ 9.5 g/dl.
- •All acute adverse effects (excluding alopecia) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have been resolved to ≤ Grade 1, except elevated liver transaminases judged to be associated with tumor infiltration (see below) (graded according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events, version 3.0 [CTCAE, v.3.0].
- •Alkaline phosphatase (AP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL unless liver involvement by the tumor, in which case the transaminase levels up to 5 x ULN are allowed.
- •Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 60 mL/min.
- •Testing negative for acute or chronic infection with hepatitis B or C virus, or human immunodeficiency virus 1 or
- •Negative pregnancy test for females of childbearing potential at the screening visit.
- •Commitment from subject to practice medically appropriate/acceptable method of birth control (e.g., hormonal, condoms or other adequate barrier controls, intrauterine contraceptive device, or sterilization) beginning at the screening visit and continuing until 3 months following the treatment with study drug
- •Able to provide written Informed Consent
- •Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
排除标准
- •Breastfeeding women
- •Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the Investigator, would place the subject at undue risk or interfere with the study.
- •Active autoimmune disease.
- •Cardiac disease as manifested by any of the following:
- •> Grade II heart failure, graded per New York Heart Association (NYHA) criteria.
- •Unstable angina pectoris
- •Acute or subacute coronary syndromes, including myocardial infarction, occurring with 1 year prior to study treatment
- •Arrhythmia needing continuous treatment
- •Ejection fraction less than the institutional lower limit of normal as assessed by multigated radionuclide angiography (MUGA) scan or echocardiogram
- •Uncontrolled hypertension.
- •History of claudication or Ischemic peripheral vascular disease (Grade IIb-IV).
- •Chronic obstructive pulmonary disease or other chronic pulmonary disease with PFTs less than 50% predicted for age.
- •Symptomatic cerebrovascular disease.
- •Active peptic ulcer disease.
- •Concurrent infection of HIV.
- •Severe diabetic retinopathy.
- •Major surgery or trauma within 4 weeks prior to start of study treatment.
- •Hypersensitivity to melphalan or TNFα or other intravenously administered human proteins/peptides/antibodies.
- •Chemotherapy, radiation therapy or therapy with an investigational agent within 4 weeks prior to start of study treatment.
- •Any regional therapy to the affected extremity within 2 months prior to start of study treatment.
- •Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
- •Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
- •Subject requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
- •Participation in another interventional clinical trial during participation in this trial.
- •Any conditions that in the opinion of the Investigator could hamper compliance with the study protocol.
结局指标
主要结局
Safety and Tolerability
时间窗: 6 weeks
The safety and tolerability profile of L19TNFα/melphalan combination treatment in the ILP setting will be determined.
Recommended dose (RD)
时间窗: 29 days
The recommended dose (RD) of L19TNFα when given in combination with melphalan in the ILP setting for subjects with limb stage III/IV melanoma will be determined.
次要结局
- Objective response rate(10 weeks)
- 5-hydroxyindoleacetic acid(10 days)
- Pharmacokinetic(10 days)
- Human anti-fusion protein antibody(6 weeks)
- Antitumor activity(4- 6 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
L19TNFα in Patients With Advanced Solid TumorsSolid TumorsColorectal CancerNCT01253837Philogen S.p.A.34
进行中（未招募）
1 期
Dose Finding Study of L19TNF and Doxorubicin in Patients With STSSoft Tissue SarcomaNCT04032964Philogen S.p.A.2
已完成
1 期
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid TumoursAdvanced Solid Tumors Amenable to Anthracycline TherapySarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline TherapyNCT02076620Philogen S.p.A.29
进行中（未招募）
不适用
Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancerHistologically or cytologically confirmed solid cancer of any pathology or adenocarcinoma of the pancreasMedDRA version: 9.1Level: LLTClassification code 10065147Term: Malignant solid tumorMedDRA version: 9.1Level: LLTClassification code 10052747Term: Adenocarcinoma pancreasEUCTR2007-001609-81-DEPhilogen S.pA.50
进行中（未招募）
2 期
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceGlioblastomaNCT06336291Philogen S.p.A.90